Oncology & Cancer

Cancer immunotherapy 'uniquely suppressed' by liver tumors

Though cancer immunotherapy has become a promising standard-of-care treatment—and in some cases, perhaps a cure—for a wide variety of different cancers, it doesn't work for everyone, and researchers have increasingly ...

Oncology & Cancer

ASCO: Cabozantinib improves progression-free survival in RCC

(HealthDay)—For patients with advanced renal cell carcinoma, cabozantinib is associated with improved progression-free survival (PFS), with consistent improvement across all patient subgroups, according to a study scheduled ...

page 1 from 4